Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Chemocentryx Inc (NQ: CCXI )

44.80 USD -1.74 (-3.74%)
Official Closing Price Updated: 7:06 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Chemocentryx Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
From GlobeNewswire News Releases
ChemoCentryx to Host Virtual R&D Day on April 14, 2021
From GlobeNewswire News Releases
ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors
From GlobeNewswire News Releases
ChemoCentryx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
From GlobeNewswire News Releases
ChemoCentryx to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
ChemoCentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer
From GlobeNewswire News Releases
ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021
From GlobeNewswire News Releases
ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
From GlobeNewswire News Releases
ChemoCentryx to Participate in Two Upcoming Investor Conferences
From GlobeNewswire News Releases
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
From GlobeNewswire News Releases
ChemoCentryx to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
ChemoCentryx Reports Third Quarter 2020 Financial Results and Recent Highlights
From GlobeNewswire News Releases
ChemoCentryx Announces Plenary Session at ACR Convergence 2020 to Highlight Findings of ADVOCATE Phase III Trial in ANCA-Associated Vasculitis
From GlobeNewswire News Releases
ChemoCentryx and VFMCRP announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
From GlobeNewswire News Releases
ChemoCentryx to Hold Third Quarter 2020 Financial Results Conference Call on Monday, November 9, 2020
From GlobeNewswire News Releases
ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)
From GlobeNewswire News Releases
ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
From GlobeNewswire News Releases
ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
From GlobeNewswire News Releases
ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights
From GlobeNewswire News Releases
ChemoCentryx to Present at Two Upcoming Investor Conferences
From GlobeNewswire News Releases
ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020
From GlobeNewswire News Releases
ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis
From GlobeNewswire News Releases
ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1... 
From GlobeNewswire News Releases
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From GlobeNewswire News Releases
ChemoCentryx Prices Public Offering of Common Stock
From GlobeNewswire News Releases
ChemoCentryx Announces Proposed Public Offering of Common Stock
From GlobeNewswire News Releases
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses
Pivotal trial demonstrated avacopan’s statistical superiority in sustaining remission at 52 weeks over the glucocorticoid-containing standard-of-care therapy 
From GlobeNewswire News Releases
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
From GlobeNewswire News Releases
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
Regulatory News: 
From Business Wire News Releases
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.